Ardelyx (ARDX) Net Income towards Common Stockholders (2013 - 2026)
Ardelyx (ARDX) reported Net Income towards Common Stockholders of -$37.6 million for Q1 2026, up 8.6% on a YoY basis from -$34.6 million in Q1 2025, and down 9139.56% quarter-over-quarter from -$407000.0 in Q4 2025.
Ardelyx (ARDX) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Ardelyx has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$37.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 8.6% year-over-year to -$37.6 million; the trailing twelve-month figure through Mar 2026 stood at -$58.1 million (down 7.99% YoY), and the FY2025 full-year result was -$61.6 million, down 57.4% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$37.6 million, down from -$407000.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $10.7 million in Q4 2022, with the low at -$41.1 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$16.0 million across 5 years, with a median of -$19.1 million in 2025.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 129.52% — and 2023, when it tumbled 369.3%.
- Ardelyx's Net Income towards Common Stockholders stood at $10.7 million in 2022, then sank by 369.3% to -$28.8 million in 2023, then soared by 116.13% to $4.6 million in 2024, then slumped by 108.76% to -$407000.0 in 2025, then slumped by 9139.56% to -$37.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$37.6 million (Q1 2026), -$407000.0 (Q4 2025), and -$969000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | -37.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.61 Mn |
| Dec 31, 2025 | -407,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -41.14 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | -16.45 Mn |
| Mar 31, 2024 | -26.52 Mn |
| Dec 31, 2023 | -28.80 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -26.77 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -26.94 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -36.23 Mn |
| Sep 30, 2021 | -43.59 Mn |
| Jun 30, 2021 | -45.19 Mn |